𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Centchroman—a non-steroidal anti-cancer agent for advanced breast cancer: Phase-II study

✍ Scribed by N. C. Misra; P. K. Nigam; Ruby Gupta; A. K. Agarwal; V. P. Kamboj

Publisher
John Wiley and Sons
Year
1989
Tongue
French
Weight
331 KB
Volume
43
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Treatment with Centchroman (3,4-trans-2,2-dimethyl-3phenyl-4-p-(fl-pyrrolidinoethoxy) phenyl-7-methoxy chroman) has been evaluated in 4 male and 75 female patients with advanced breast cancer. The overall response rate, including both male and female cases, was 40.5%. Among the female patients, the overall response rate was 38.7%. The median duration of response was 6 months. One of the 4 male patients showed a complete response and 2 showed partial responses. The responses were more marked for bone, pulmonary, soft tissue, skin and lymph-node metastases than for liver metastases.

📜 SIMILAR VOLUMES

A phase II study of oral idarubicin (4-d
A phase II study of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancer
✍ Nicholas S. A. Stuart; Michael H. Cullen; Terrence J. Priestman; George R. P. Bl 📂 Article 📅 1988 🏛 Springer 🌐 English ⚖ 352 KB

Idarubicin (4-demethoxydaunorubicin: DMDNR) is an orally active analogue of daunorubicin that has shown promising activity in animal and early clinical studies. We gave idarubicin in a phase II study to patients with advanced breast cancer unresponsive to hormonal manipulation and in some cases to s

A phase II study of high-dose medroxypro
A phase II study of high-dose medroxyprogesterone acetate in advanced breast cancer
✍ Geoffrey Falkson; Hèndré C. Falkson 📂 Article 📅 1983 🏛 Springer 🌐 English ⚖ 215 KB

Twenty-three evaluable patients with advanced breast cancer were treated with MPA, 1,400 mg/m2 daily PO for the first 6 months, and 500 mg/m2 daily PO thereafter. The median total dose was 191,400 mg in 88 days, with the maximum dose given to date 522,600 mg in 282 days. Most patients tolerated high